<DOC>
	<DOCNO>NCT00326989</DOCNO>
	<brief_summary>Extracorporal shock wave therapy perform prior cell therapy induction therapeutic neovascularization improvement home bone marrow progenitor cell patient chronic ischemic heart disease follow anterior myocardial infarction . Shock wave induce growth factor expression ischemic myocardium might augment home autologous bone marrow mononuclear cell inject intracoronary 24 h follow shock wave therapy</brief_summary>
	<brief_title>Cell-Wave Study : Combined Extracorporal Shock Wave Therapy Intracoronary Cell Therapy Chronic Ischemic Myocardium</brief_title>
	<detailed_description>Single center , Phase I-II Study ( Safety , Feasibility Efficacy ) Double-blind , randomise trial ( Cell therapy ) , single blind ( Shockwave )</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Patients chronic ischemic heart disease Patients anterior myocardial infarction &gt; 3months EF &lt; 50 % NYHA IIIV Age 1880 Informed consent Ventricular thrombus Infarct &lt; 3 month . Active infection fever Chronic inflammatory disease ( e.g M. Crohn , Rheumatoid Arthritis ) HIV Infection oder active Hepatitis Neoplastic disease w/o complete remission within 5 year Stroke &lt; 3months Creatinine &gt; 2 mg/dl Relevant Liver disease ( GOT &gt; twice upper limit ) . Anemia ( Hemoglobin &lt; 10 mg/dl ) Thrombocytopenia &lt; 100.000/Âµl Allergies Aspirin , Clopidogrel , Heparin History bleed disorder History coagulopathy Gastrointestinal Bleeding &lt; 3 month Surgery Trauma &lt; 2 month Pregnancy Mental Retardation Participation clinical study &lt; 1 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Extracorporal shock wave therapy</keyword>
	<keyword>Cell therapy</keyword>
</DOC>